2025-08-21 - Analysis Report
Okay, here's a report analyzing Johnson & Johnson (JNJ) based on the provided data.

## Johnson & Johnson (JNJ) Analysis

Johnson & Johnson is a global healthcare company that researches, develops, manufactures, and sells a broad range of products in the healthcare field.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (JNJ):** 3.95%
*   **Cumulative Return (VOO):** 37.28%
*   **Absolute Deviation:** -71.2
*   **Relative Deviation:** 11.5

**Analysis:** JNJ has significantly underperformed the S&P 500 (VOO) over the analyzed period.  The relative deviation of 11.5 indicates that JNJ's underperformance is near the lowest end of its historical range compared to the S&P 500. This means that the underperformance is more extreme compared to its own historical data.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha  | Beta  | Cap(B) |
|------------|---------|--------|--------|-------|--------|
| 2015-2017  | 0.0%    | 0.0%   | 0.0%   | 1.0   | 336.5  |
| 2016-2018  | 0.0%    | 0.0%   | 0.0%   | 1.0   | 310.8  |
| 2017-2019  | 0.0%    | 0.0%   | 0.0%   | 1.0   | 351.3  |
| 2018-2020  | 0.0%    | 0.0%   | 0.0%   | 1.0   | 379.0  |
| 2019-2021  | 4.0%    | 0.0%   | 3.0%   | 0.1   | 412.0  |
| 2020-2022  | -1.0%   | 61.2%  | 10.0%  | 0.0   | 425.4  |
| 2021-2023  | -4.0%   | 61.2%  | -13.0% | -0.0  | 377.5  |
| 2022-2024  | -18.0%  | 61.2%  | -48.0% | -0.1  | 348.3  |
| 2023-2025  | 10.0%   | 70.0%  | -33.0% | -0.1  | 430.7  |

**Analysis:**

*   **CAGR:** Varies significantly, showing periods of both growth and decline. Recent years (2022-2024) show a notable decline.
*   **MDD:** Maximum Drawdown is significant in recent periods, suggesting considerable risk.
*   **Alpha:** Often negative, indicating underperformance relative to the benchmark.
*   **Beta:** Generally low, implying lower volatility compared to the market, but recently negative.
*   **Cap(B):** Market capitalization is substantial, indicating a large and established company.

### 2. Recent Price Action

*   **Current Price:** 178.84
*   **Previous Close:** 177.8
*   **Change:** 0.58
*   **5-day Moving Average:** 176.85
*   **20-day Moving Average:** 171.701
*   **60-day Moving Average:** 161.271

**Analysis:** The stock price is trading above its 5-day, 20-day, and 60-day moving averages, suggesting a short-term uptrend. The relatively large change from the previous close (0.58) indicates potential momentum.

### 3. Technical Indicators and Outlook

*   **Market Risk Indicator (MRI):** 0.3316 (Low Risk)
*   **RSI:** 89.47 (Overbought)
*   **PPO:** 0.1395
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Delta_Previous_Relative_Divergence:** 0.0 (Neutral)
*   **Expected Return:** -236.2%

**Analysis:**

*   **MRI:**  Indicates a low-risk environment.
*   **RSI:**  The RSI is extremely high, suggesting the stock is overbought and may be due for a correction.
*   **PPO:** Positive, indicating the price is above its moving average, confirming the uptrend.
*   **Hybrid Signal:** The hybrid signal suggests caution, likely due to the high RSI, despite the low MRI. It recommends buying 80% of available cash.
*   **Delta_Previous_Relative_Divergence:** Neutral suggesting recent uptrend.
*   **Expected Return:** The negative expected return suggests that long-term returns may be significantly lower than the S&P 500.

### 4. Recent News & Significant Events

*   **Business Developments/Regulatory Changes:** JNJ has recently been in the news due to major business developments, regulatory changes, or market events.
*   **Analyst Discussions:** Analysts are discussing JNJ's recent performance in the context of industry trends and global economic factors.
*   **Volatility:** JNJ's stock has shown notable volatility.
*   **Risks and Opportunities:** Market experts highlight both risks and opportunities.

**Analysis:**  The recent news suggests a dynamic environment for JNJ, with both opportunities and risks. Increased volatility and analyst scrutiny are worth noting.

### 5. Recent Earnings Analysis

| 날짜         | EPS   | 매출        |
|--------------|-------|-------------|
| 2025-07-24   | 2.3   | 23.74 B$    |
| 2025-04-23   | 4.57  | 21.89 B$    |
| 2024-10-23   | 1.12  | 22.47 B$    |
| 2024-07-25   | 1.95  | 22.45 B$    |
| 2025-07-24   | 1.95  | 22.45 B$    |

**Analysis:** Recent data shows inconsistent growth and some anomalies. The most recent EPS is at 2.3 with revenue at $23.74B. The data seems partially duplicated or inconsistent, requiring validation.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $23.74B    | 67.87%        |
| 2025-03-31   | $21.89B    | 66.40%        |
| 2024-12-31   | $22.52B    | 68.35%        |
| 2024-09-30   | $22.47B    | 69.01%        |
| 2024-06-30   | $22.45B    | 69.40%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-06-30   | $78.47B    | 7.06%     |
| 2025-03-31   | $78.11B    | 14.08%    |
| 2024-12-31   | $71.49B    | 4.80%     |
| 2024-09-30   | $70.16B    | 3.84%     |
| 2024-06-30   | $71.54B    | 6.55%     |

**Analysis:**

*   **Revenue:**  Relatively stable revenue stream with recent growth.
*   **Profit Margin:** Consistently high profit margins, indicating strong profitability.
*   **Equity:**  Growing equity base.
*   **ROE:**  Fluctuating ROE, with recent values being higher than previous quarters.

### 7. Overall Summary and Conclusion

Johnson & Johnson (JNJ) is currently exhibiting a mixed outlook. While the company has a strong financial foundation (high profit margins, substantial equity), it has significantly underperformed the S&P 500. Recent price action suggests a short-term uptrend, but the extremely high RSI indicates the stock is overbought and may be due for a correction. Analyst discussions and recent news suggest potential for both opportunities and risks.  The negative long-term expected return is concerning and warrants further investigation.

**Recommendations:**

*   **Caution Advised:** Given the overbought conditions and negative long-term outlook, caution is advised.
*   **Monitor News:** Closely monitor news and company announcements for developments that could impact the stock.
*   **Further Research:** Investigate the reasons behind the underperformance relative to the S&P 500 and the negative long-term expected return. Validate the earnings data provided.

This report provides a snapshot of JNJ based on the provided data.  A more comprehensive analysis would require additional data and deeper investigation.
